Verified Peptide ReviewLast reviewed: 8 March 2026
Compound Profile · Sexual Health
PT-141
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist approved in some jurisdictions for hypoactive sexual desire disorder in premenopausal women.
LegalPrescriptionEvidenceEmergingHuman useApproved
6.8/ 10
Peptide Score
Evidence
Safety
Regulatory
Transparency
Quick verdict
Has an approved indication and clinical evidence base. Adverse-event profile is meaningful.
Reality check
What this isn't
- Evidence base is early — long-term data limited
- Side-effect profile not fully characterised
- Educational only — not medical advice
Full PT-141 review
A selective melanocortin receptor agonist.
Looking at alternatives?
Compounds with comparable research interest but different evidence, regulatory status, or risk profile.